Figure 3.

BEAS-2B epithelial barrier impairment mediated by NSCLC EVs. (A) Schematic representing the design of epithelial barrier impairment studies. (B) Trans-epithelial electrical barrier (TEER) progression of the BEAS-2B epithelial barrier over 10 days. The TEER prior to EV treatment (on day 8) was 39.01 ± 2.4 Ω.cm². (C) TEER progression after treatment of an eight-day mature BEAS-2B epithelial barrier with non-tumorigenic or cancer cell derived EVs (n = 3). The bar graph represents TEER at the end of the 48 h after treatment. P-values for TEER progression and bar graph were computed using unpaired t-test with Welch’s correction and ANOVA followed by Dunnett’s multiple comparison tests, respectively. (D) BEAS-2B epithelial barrier permeability measured by apical-to-basal translocation kinetics of 70 kDa RITC-Dextran after treatment with normal or cancer EVs (n = 3). The bar graph represents the fold-change in the amount of RITC-Dextran in the basal chamber after 2 h of the 48 h treatment. P-values for dextran translocation kinetics and bar graph were computed using unpaired t-test with Welch’s correction and ANOVA followed by Dunnett’s multiple comparison tests, respectively. The UT is normalized to 1 μg/ml. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.00001.